Imbalance between neutral endopeptidase 24.11 and endothelin-1 expression in human endometrial carcinoma. 2001

T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Nagoya, Japan.

OBJECTIVE Neutral endopeptidase 24.11 (NEP)/CD10 is a cell-surface peptidase that degrades various bioactive peptides including endothelin-1 (ET-1). This enzyme is known to play a role in maintaining ET-1-regulated vascular homeostasis in the normal human endometrium. The purpose of the present study was to investigate the expression and localization of NEP and ET-1 in neoplastic endometria, and also to clarify the correlation of their expression with the tumor grade of endometrial carcinoma. METHODS Immunohistochemical analysis for NEP and ET-1 expression was performed on paraffin-embedded tissue sections of 7 normal endometria (after menopause), 5 atypical endometrial hyperplasias (AEH), and 32 endometrial endometrioid adenocarcinomas. RESULTS In normal endometrium and AEH, NEP immunoreactivity was detected in stromal cells, but not in glandular cells. In contrast, ET-1 immunoreactivity was detected in both glandular and stromal cells. In the stromal cells of grade 1 endometrial adenocarcinoma, NEP was detected at high or moderate quantities. However, significantly decreased NEP immunoreactivity was observed in the stromal cells of grade 2 and 3 adenocarcinomas. However, NEP was not immunostained in adenocarcinoma cells except for the lesions of squamous differentiation. ET-1 immunoreactivity was weakly detected in the stromal cells of grade 1 adenocarcinoma, but the intensity of ET-1 staining increased with advancing tumor grade. The ratio of the staining scores of stromal ET-1 to stromal NEP was positively correlated with the tumor grade. CONCLUSIONS These findings demonstrate that NEP expression in the stromal cells of endometrial adenocarcinoma is downregulated, while stromal ET-1 is upregulated, with increasing tumor grade. The present findings also suggest that NEP may play a role in the regulation of neoplastic transformation, tumor progression, and differentiation in endometrial neoplasms, possibly by degrading certain peptide growth factors such as ET-1.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015260 Neprilysin Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT. Antigens, CD10,Antigens, Leukemia, Common Acute Lymphoblastic,CALLA Antigen,CD10 Antigens,Common Acute Lymphoblastic Leukemia Antigens,Endopeptidase-24.11,Enkephalin Dipeptidyl Carboxypeptidase,Enkephalinase,Kidney-Brush-Border Neutral Proteinase,Membrane Metallo-Endopeptidase,Atriopeptidase,CD10 Antigen,Enkephalinase-24.11,Neutral Endopeptidase,Neutral Endopeptidase 24.11,Thermolysin-Like Metalloendopeptidase,YGG-Forming Enzyme,Antigen, CD10,Carboxypeptidase, Enkephalin Dipeptidyl,Dipeptidyl Carboxypeptidase, Enkephalin,Endopeptidase 24.11,Endopeptidase 24.11, Neutral,Endopeptidase, Neutral,Enkephalinase 24.11,Enzyme, YGG-Forming,Kidney Brush Border Neutral Proteinase,Membrane Metallo Endopeptidase,Metallo-Endopeptidase, Membrane,Metalloendopeptidase, Thermolysin-Like,Neutral Proteinase, Kidney-Brush-Border,Thermolysin Like Metalloendopeptidase,YGG Forming Enzyme
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D019332 Endothelin-1 A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63) Big Endothelin,Big Endothelin-1,Endothelin Type 1,Endothelin, Big,Preproendothelin,Preproendothelin-1,Proendothelin (1-38),Proendothelin-1 Precursor,Big Endothelin 1,Endothelin 1,Endothelin-1, Big,Precursor, Proendothelin-1,Preproendothelin 1,Proendothelin 1 Precursor

Related Publications

T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
January 1995, British journal of cancer,
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
May 1996, Immunopharmacology,
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
August 2002, Clinical science (London, England : 1979),
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
August 1995, Hypertension (Dallas, Tex. : 1979),
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
January 1994, Laboratory investigation; a journal of technical methods and pathology,
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
August 2002, Clinical science (London, England : 1979),
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
July 2006, Cancer science,
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
December 1987, The Biochemical journal,
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
January 1991, Peptides,
T Suzuki, and F Kikkawa, and K Ino, and T Nagasaka, and K Tamakoshi, and S Mizutani
January 1988, Advances in experimental medicine and biology,
Copied contents to your clipboard!